Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database

Cancer
Jorge J CastilloSteven P Treon

Abstract

Waldenström macroglobulinemia (WM) is an indolent malignancy that predominantly affects older individuals who are at risk for secondary malignancies (SMs). The objective of this study was to characterize the incidence of SMs after a diagnosis of WM with the Surveillance, Epidemiology, and End Results (SEER) database. With SEER-13 data (1992-2011), standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for the rates of solid and hematologic SMs in WM patients versus the general population. The analysis was stratified by age, sex, race, year of diagnosis, and latency from the WM diagnosis. Among 4676 patients with WM, 681 SMs were recorded. The overall SIR was 1.49 (95% CI, 1.38-1.61), and the median time to an SM was 3.7 years. The cumulative incidence of SMs was 10% at 5 years and 16% at 10 years. The risk was significantly increased for cancers of the lungs, urinary tract, and thyroid; melanoma; aggressive lymphoma; and acute leukemia. The SIR for SMs in patients with WM was increased, regardless of age, sex, race, or year of diagnosis. Patients with WM had a 49% higher risk of SMs than the general population. The selectively increased risk for hematologic SMs and certain solid SMs may be assoc...Continue Reading

References

Jun 4, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W Y AuJ M Connors
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vicki A MorrisonCharles A Schiffer
Dec 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S P TreonC C Morton
Sep 7, 2006·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Octavio A CastilloGonzalo Vitagliano
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Luca ArcainiMario Lazzarino
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J Dignam, Maria N Kocherginsky
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier LeleuSteven P Treon
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Apostolia-Maria TsimberidouMichael J Keating
Nov 12, 2009·Haematologica·Zachary R HunterSteven P Treon
Oct 5, 2010·International Journal of Cancer. Journal International Du Cancer·Jill S RoyleLin Fritschi
Oct 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lindsay M MortonJoseph F Fraumeni
Apr 2, 2011·Clinical Lymphoma, Myeloma & Leukemia·Christina HanzisSteven P Treon
Apr 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M VarettoniE Morra
Nov 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R P Ojha, R Thertulien
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique LeblondRoger G Owen
Nov 20, 2013·Nature Reviews. Clinical Oncology·Charles G DrakeJulie R Brahmer
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto

❮ Previous
Next ❯

Citations

Jul 15, 2016·American Journal of Hematology·Jorge J CastilloSteven P Treon
Oct 25, 2016·Annales de dermatologie et de vénéréologie·C VelterB Cribier
Jul 10, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E KastritisUNKNOWN ESMO Guidelines Committee
Nov 17, 2016·Oncotarget·Sarah BertoliChristian Récher
Dec 21, 2018·Aging·Maria GavriatopoulouMeletios Athanasios Dimopoulos
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E KastritisUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.